BRPI0813094A2 - Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica. - Google Patents

Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.

Info

Publication number
BRPI0813094A2
BRPI0813094A2 BRPI0813094-9A2A BRPI0813094A BRPI0813094A2 BR PI0813094 A2 BRPI0813094 A2 BR PI0813094A2 BR PI0813094 A BRPI0813094 A BR PI0813094A BR PI0813094 A2 BRPI0813094 A2 BR PI0813094A2
Authority
BR
Brazil
Prior art keywords
carboxamides
pyrorolo
hydro
tetra
derivatives
Prior art date
Application number
BRPI0813094-9A2A
Other languages
English (en)
Inventor
Bernard Baudoin
Michel Evers
Arielle Genevois-Borella
Andreas Karlsson
Jean-Luc Malleron
Magali Mathieu
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0705498A external-priority patent/FR2919289B1/fr
Priority claimed from FR0705497A external-priority patent/FR2919288B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0813094A2 publication Critical patent/BRPI0813094A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0813094-9A2A 2007-07-27 2008-07-24 Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica. BRPI0813094A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705498A FR2919289B1 (fr) 2007-07-27 2007-07-27 Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR0705497A FR2919288B1 (fr) 2007-07-27 2007-07-27 Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
PCT/FR2008/001096 WO2009044007A2 (fr) 2007-07-27 2008-07-24 Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
BRPI0813094A2 true BRPI0813094A2 (pt) 2014-12-23

Family

ID=40526763

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813094-9A2A BRPI0813094A2 (pt) 2007-07-27 2008-07-24 Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.

Country Status (23)

Country Link
US (1) US20100197668A1 (pt)
EP (1) EP2185561B1 (pt)
JP (1) JP2010534639A (pt)
KR (1) KR20100050485A (pt)
CN (1) CN101765601A (pt)
AT (1) ATE512968T1 (pt)
AU (1) AU2008306835A1 (pt)
BR (1) BRPI0813094A2 (pt)
CA (1) CA2694288A1 (pt)
CO (1) CO6290689A2 (pt)
CY (1) CY1112121T1 (pt)
DK (1) DK2185561T3 (pt)
EA (1) EA201070195A1 (pt)
HR (1) HRP20110650T1 (pt)
MA (1) MA31630B1 (pt)
MX (1) MX2010001076A (pt)
NZ (1) NZ582871A (pt)
PL (1) PL2185561T3 (pt)
PT (1) PT2185561E (pt)
RS (1) RS51912B (pt)
SI (1) SI2185561T1 (pt)
WO (1) WO2009044007A2 (pt)
ZA (1) ZA201000581B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919285B1 (fr) * 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
US8822527B2 (en) 2011-10-17 2014-09-02 Biotheryx, Inc. Substituted biaryl alkyl amides
US9284333B2 (en) 2012-02-03 2016-03-15 Sanofi Fused pyrroledicarboxamides and their use as pharmaceuticals
US10431748B2 (en) 2014-10-30 2019-10-01 Lg Chem, Ltd. Cyclic compound and organic light-emitting element comprising same
US10301306B2 (en) 2014-12-15 2019-05-28 Bristol-Myers Squibb Company Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
CN114522668B (zh) * 2022-01-13 2023-10-13 浙江大学杭州国际科创中心 乙氧基柱[6]芳烃晶体材料在选择性吸附四氢吡咯中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003070730A1 (ja) * 2002-02-22 2005-06-09 帝人株式会社 ピロロピリミジン誘導体
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CY1112121T1 (el) 2015-11-04
WO2009044007A3 (fr) 2009-09-17
DK2185561T3 (da) 2011-10-10
EP2185561A2 (fr) 2010-05-19
EP2185561B1 (fr) 2011-06-15
AU2008306835A1 (en) 2009-04-09
ZA201000581B (en) 2011-04-28
NZ582871A (en) 2011-09-30
KR20100050485A (ko) 2010-05-13
EA201070195A1 (ru) 2010-10-29
PL2185561T3 (pl) 2011-11-30
MX2010001076A (es) 2010-03-09
PT2185561E (pt) 2011-09-07
CA2694288A1 (fr) 2009-04-09
MA31630B1 (fr) 2010-08-02
JP2010534639A (ja) 2010-11-11
WO2009044007A2 (fr) 2009-04-09
HRP20110650T1 (hr) 2011-10-31
CO6290689A2 (es) 2011-06-20
SI2185561T1 (sl) 2011-10-28
US20100197668A1 (en) 2010-08-05
RS51912B (en) 2012-02-29
CN101765601A (zh) 2010-06-30
ATE512968T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
NI200800207A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
HN2009000784A (es) Dihidropirazolonas sustituidas
BRPI0810412A2 (pt) Derivados de triazolo piridina-carboxamidas e triazolo pirimidina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
MY153921A (en) Aminopyrazole derivatives
BRPI0813094A2 (pt) Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI0923875A2 (pt) Derivados de 2-piridin-2-il-pirazol-3 (2h)-ona, o respectivo preparo e a respectiva aplicação terapêutica.
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
BRPI0923182A2 (pt) derivados de 6-cicloamino-2,3-di-piridinil-imidazo[1,2-b]piridazina, o respectivo preparo e a respectivo preparo e a respectiva aplicação terapêutica
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
BRPI0822054A2 (pt) Derivados de azetidinas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0821426A2 (pt) Compostos de n-fenil-imidazol[1,2-a]piridina-2-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI0806969A2 (pt) Derivados de azabicicloalcano, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0821674A2 (pt) Derivados de n-fenil-imidazo[1,2-a] piridina-2- carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
BRPI0812588A2 (pt) Derivados de 1-benzilpirazol, o respectivo preparo e a respectiva aplicação em terapêutica
WO2007121883A3 (de) 1,4:3,6-dianhydromannitol-derivate und deren verwendung
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble
BRPI0813624A2 (pt) derivados de 1-oxo-isoindolina-4-carboxamidas e de 1-oxo-1,2,3,4-tetra-hidroisoquinoleína-5-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica.
BRPI0821823A2 (pt) Derivados de n-heterocíclico-6-heterocíclico-imidazo[1,2-a]piridin a-2-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
UY30236A1 (es) Inhibidores de la adenilato ciclasa soluble
DOP2007000060A (es) Inhibidores de la adenilato ciclasa soluble
EP1968383A4 (en) Heterocycles and their derivatives, method of preparation and their use in therapy
UY29583A1 (es) Inhibidores de la adenilato ciclasa soluble
BRPI1008544A2 (pt) derivados de n-[(6-aza-biciclo [3.2.1] oct-1-il)-aril-metil]-benzamida, o respectivo preparo e a respectiva aplicação em terapêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.